Acetylon moving to Boston’s Seaport Center
Article Courtesy of: www.masshightech.com
Biotech Acetylon Pharmaceuticals Inc. is moving from its Albany Street location in Boston to the Seaport Center near the South Boston waterfront.
Acetylon is developing selective small molecule histone deacetylase (HDAC) inhibitors and other targeted drugs for the treatment of cancers, and for inflammatory, neurodegenerative, genetic and infectious diseases.
The company has leased 9,700 square feet of space for its new headquarters, including office and lab space, as well as two biosafety level 2 labs that are scheduled to be completed this summer. According to realtor Jones Lang LaSalle, which represented the property owner Beal Companies, Acetylon is the first R&D tenant in Seaport Center.
The news came just a week after Acetylon bumped up its Series B funding to $27 million, and closed the round short of its initial stated goal of $30 million.
Innovation District lures another drug company
Another pharmaceutical company is headed to the Innovation District in South Boston.
Acetylon Pharmaceuticals will relocate to Seaport Center Boston, where it will lease 9,700 square feet of headquarters and lab space, according to Jones Lang LaSalle, the property’s leasing agent.
Acetylon is developing small molecule drugs to treat cancer, autoimmune and other diseases. Its new location will include research and development lab space and two Biosafety Level 2 labs. Construction on the second-floor space is expected to be finished this summer.
The company is relocating to the Fargo Street building from Boston’s Albany Street.
Cambridge’s Brightcove moving to Atlantic Wharf in Hub